alexion
pharmceuticals
said
friday
c5
inhibitor
drug
reported
block
cell
death
heart
tissue
resulting
myocardial
infarctions.alexion
said
preclinical
findings
presented
annual
vascular
biology
meeting
dr
gregory
stahl
harvard
medical
school.alexion
completed
phase
safety
trial
5g1.1-sc
lead
complement
inhibitor
product
currently
tested
phase
ii
clinical
trial.alexion
based
new
haven
conn
develops
immunotherapeutic
drugs
